In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.

Topics include:

• Supportive care as the foundation of IgAN management
• Place in therapy for new and emerging agents
  • Targeted-release formulation of budesonide
  • Endothelin receptor antagonists (eg, sparsentan)
  • Factor B inhibitors (eg, iptacopan)
• The role of clinical trial involvement

Learn more about IgA nephropathy with educational activities and resources here:

• CME-certified text module with animated pathophysiology video and patient voice audio clip
• ClinicalThought commentaries
• Resources on IgAN from the American Kidney Fund

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

• Colchicine: inhibition of NLRP3 inflammasome assembly/activation
• Canakinumab (anti–IL-1β monoclonal antibody)
• Ziltivekimab (anti–IL-6 monoclonal antibody)
• Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.  

 Episode outline:  

• The relationship among systemic inflammation, ASCVD, and CKD
• The role of cardiologists and nephrologists in screening and mitigating systemic inflammation

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
• Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

• Moving beyond lipid lowering to address residual inflammatory risk
• Novel anti-inflammatory targets for ASCVD

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
• Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD

In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases.

Episode outline:

• Seeking and obtaining an IgAN diagnosis
• Patient self-advocacy
• Individualizing IgAN treatment plans
• Clinical trial involvement
• Burdens of IgAN: physical, emotional, social, and beyond

To learn more about IgA nephropathy, find more educational activities and resources with the links below:

• CME-certified text module with animated pathophysiology video and patient voice audio clips
• ClinicalThought commentaries
• Resources on IgAN from the American Kidney Fund

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:

• Patient subgroups to consider for treatment outside guideline criteria
• Adverse event and cost-effectiveness considerations
• Integration of patient perspectives in wider treatment

Presenters:

Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Jacki Chen, PhD
Patient Advocate

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/4a60GM4

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies.

Presenters:

Arun B. Jesudian, MD
Associate Professor of Clinical Medicine
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Mazen Noureddin, MD, MHSc
Professor of Medicine
Houston Methodist Hospital
Director
Houston Research Institute
Houston, Texas

Content based on an online CME program supported by independent educational grants from Novo Nordisk.

To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.

Link to full program:
https://bit.ly/3Tyu7At

In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:

• Beneficial effects beyond glycemic control 
• Adverse events and how to manage them
• Non- or partial responders and the importance of setting expectations with patients 
• Weight rebound when discontinuing therapy
• Medication access issues related to cost and drug availability 

Presenters:

Jennifer Green, MD
Professor of Medicine
Division of Endocrinology and Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Carol Hatch Wysham, MD
Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Link to online program: 
https://bit.ly/48b6XnW